- Home
- SKIL vs DMAC Comparison
SKIL vs DMAC Comparison
Compare SKIL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIL
- DMAC
- Stock Information
- Founded
- SKIL 1998
- DMAC 2000
- Country
- SKIL United States
- DMAC United States
- Employees
- SKIL N/A
- DMAC N/A
- Industry
- SKIL Computer Software: Prepackaged Software
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SKIL Technology
- DMAC Health Care
- Exchange
- SKIL Nasdaq
- DMAC Nasdaq
- Market Cap
- SKIL 166.4M
- DMAC 158.1M
- IPO Year
- SKIL N/A
- DMAC N/A
- Fundamental
- Price
- SKIL $20.32
- DMAC $4.11
- Analyst Decision
- SKIL
- DMAC Strong Buy
- Analyst Count
- SKIL 0
- DMAC 2
- Target Price
- SKIL N/A
- DMAC $8.00
- AVG Volume (30 Days)
- SKIL 21.9K
- DMAC 102.4K
- Earning Date
- SKIL 06-09-2025
- DMAC 05-13-2025
- Dividend Yield
- SKIL N/A
- DMAC N/A
- EPS Growth
- SKIL N/A
- DMAC N/A
- EPS
- SKIL N/A
- DMAC N/A
- Revenue
- SKIL $530,994,000.00
- DMAC N/A
- Revenue This Year
- SKIL $3.19
- DMAC N/A
- Revenue Next Year
- SKIL $2.46
- DMAC N/A
- P/E Ratio
- SKIL N/A
- DMAC N/A
- Revenue Growth
- SKIL N/A
- DMAC N/A
- 52 Week Low
- SKIL $8.05
- DMAC $2.14
- 52 Week High
- SKIL $34.43
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- SKIL 49.12
- DMAC 50.90
- Support Level
- SKIL $19.05
- DMAC $3.92
- Resistance Level
- SKIL $20.76
- DMAC $4.33
- Average True Range (ATR)
- SKIL 1.18
- DMAC 0.29
- MACD
- SKIL -0.12
- DMAC 0.02
- Stochastic Oscillator
- SKIL 27.42
- DMAC 56.79
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experience learner platform that serves learners world-wide. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.